Fate Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today its participation in the following upcoming investor conferences:
- Guggenheim Healthcare Talks | Oncology Day on Thursday, February 13, 2020 at 11:30 a.m. ET in New York, NY.
- 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 3:30 p.m. ET in New York, NY.
- Barclays Global Healthcare Conference on Thursday, March 12, 2020 at 8:30 a.m. ET in Miami, FL.
- Oppenheimer's 30th Annual Healthcare Conference on Wednesday, March 18, 2020 at 1:00 p.m. ET in New York, NY.
A live webcast of each presentation will be available through the investor relations section of the Company's website at . Following each live webcast, an archived replay will be available on the Company's website.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit .
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
